Neo-adjuvant Simvastatin therapy in colorectal cancer

Primary objectives: To ascertain whether orally delivered Simvastatin affects levels of apoptosis, proliferation and bone morphogenetic protein pathway activation in colorectal cancer in humans. Primary endpoints: Levels of BMP2 and 4 and phospho-Smad1 in surgical resection specimens.levels of apoptosis and proliferation in surgical resection specimenslevels of angiogenesis in surgical resection specimens